country,alpha_2_code,alpha_3_code,numeric_code,indicator,time_period,obs_value,sex,unit_multiplier,unit_of_measure,observation_status,observation_confidentaility,time_period_activity_related_to_when_the_data_are_collected,current_age
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,1.5,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,<1,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,<1,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,2.4,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,3.8,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,3.3,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,3.8,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,8.6,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,8.7,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,11.8,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,12.6,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,18.6,Total,Units,%,Estimated value,Free,,Total
Afghanistan,AF,AFG,4,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,15.1,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,37.4,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,34.6,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,28.5,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,42.3,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,20.8,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,18.4,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,30.8,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,36.6,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,42.6,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,45.4,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,31.5,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,22.8,Total,Units,%,Estimated value,Free,,Total
Algeria,DZ,DZA,12,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,25.5,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,14.2,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,9.7,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,11.7,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,20.4,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,31.4,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,29.8,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,27.3,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,26.0,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,36.1,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,57.7,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,65.5,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,74.9,Total,Units,%,Estimated value,Free,,Total
Angola,AO,AGO,24,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,79.5,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,8.7,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,15.2,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,20.0,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,30.7,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,45.1,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,55.4,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,75.3,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,84.8,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,70.9,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,94.3,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,79.7,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,67.1,Total,Units,%,Estimated value,Free,,Total
Azerbaijan,AZ,AZE,31,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,61.5,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,5.8,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,2.6,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,4.4,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,4.7,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,6.2,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,5.0,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,5.0,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,5.5,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,7.7,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,6.0,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,3.7,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,7.7,Total,Units,%,Estimated value,Free,,Total
Bangladesh,BD,BGD,50,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,4.4,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,94.6,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,>95,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,>95,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,69.7,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,78.6,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,79.1,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,58.5,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,67.2,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,74.2,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,67.8,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,72.1,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,73.3,Total,Units,%,Estimated value,Free,,Total
Belize,BZ,BLZ,84,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,72.9,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,12.9,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,16.8,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,19.2,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,18.0,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,30.4,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,65.6,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,73.2,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,65.3,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,72.7,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,87.5,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,94.5,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,85.7,Total,Units,%,Estimated value,Free,,Total
Benin,BJ,BEN,204,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,93.6,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,25.0,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,31.6,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,46.6,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,39.3,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,42.1,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,51.6,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,61.9,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,92.9,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,80.9,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,83.6,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,72.7,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,82.7,Total,Units,%,Estimated value,Free,,Total
"Bolivia, Plurinational State of",BO,BOL,68,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,87.6,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,70.4,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,64.0,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,80.5,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,82.1,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,75.4,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,78.8,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,78.4,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,88.8,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Botswana,BW,BWA,72,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,32.3,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,36.6,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,39.0,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,42.0,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,55.5,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,40.2,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,45.6,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,51.5,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,57.6,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,64.4,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,71.7,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,79.7,Total,Units,%,Estimated value,Free,,Total
Burkina Faso,BF,BFA,854,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,83.8,Total,Units,%,Estimated value,Free,,Total
Burundi,BI,BDI,108,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Burundi,BI,BDI,108,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Burundi,BI,BDI,108,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,85.1,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,>95,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,>95,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,63.5,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Cape Verde,CV,CPV,132,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,93.7,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,37.2,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,49.0,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,53.5,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,60.8,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,68.7,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,79.8,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,81.7,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,92.8,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,87.2,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,82.5,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,89.4,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,75.4,Total,Units,%,Estimated value,Free,,Total
Cambodia,KH,KHM,116,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,88.6,Total,Units,%,Estimated value,Free,,Total
Cameroon,CM,CMR,120,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,42.2,Total,Units,%,Estimated value,Free,,Total
Cameroon,CM,CMR,120,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,48.6,Total,Units,%,Estimated value,Free,,Total
Cameroon,CM,CMR,120,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,57.5,Total,Units,%,Estimated value,Free,,Total
Cameroon,CM,CMR,120,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,76.7,Total,Units,%,Estimated value,Free,,Total
Cameroon,CM,CMR,120,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,75.6,Total,Units,%,Estimated value,Free,,Total
Cameroon,CM,CMR,120,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,91.5,Total,Units,%,Estimated value,Free,,Total
Cameroon,CM,CMR,120,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,79.7,Total,Units,%,Estimated value,Free,,Total
Cameroon,CM,CMR,120,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,81.3,Total,Units,%,Estimated value,Free,,Total
Cameroon,CM,CMR,120,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,78.5,Total,Units,%,Estimated value,Free,,Total
Cameroon,CM,CMR,120,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,63.6,Total,Units,%,Estimated value,Free,,Total
Cameroon,CM,CMR,120,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,64.9,Total,Units,%,Estimated value,Free,,Total
Cameroon,CM,CMR,120,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,70.0,Total,Units,%,Estimated value,Free,,Total
Cameroon,CM,CMR,120,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,67.7,Total,Units,%,Estimated value,Free,,Total
Central African Republic,CF,CAF,140,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,23.7,Total,Units,%,Estimated value,Free,,Total
Central African Republic,CF,CAF,140,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,30.7,Total,Units,%,Estimated value,Free,,Total
Central African Republic,CF,CAF,140,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,34.2,Total,Units,%,Estimated value,Free,,Total
Central African Republic,CF,CAF,140,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,20.1,Total,Units,%,Estimated value,Free,,Total
Central African Republic,CF,CAF,140,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,34.7,Total,Units,%,Estimated value,Free,,Total
Central African Republic,CF,CAF,140,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,38.7,Total,Units,%,Estimated value,Free,,Total
Central African Republic,CF,CAF,140,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,55.0,Total,Units,%,Estimated value,Free,,Total
Central African Republic,CF,CAF,140,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,40.1,Total,Units,%,Estimated value,Free,,Total
Central African Republic,CF,CAF,140,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,43.6,Total,Units,%,Estimated value,Free,,Total
Central African Republic,CF,CAF,140,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,54.2,Total,Units,%,Estimated value,Free,,Total
Central African Republic,CF,CAF,140,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,47.6,Total,Units,%,Estimated value,Free,,Total
Central African Republic,CF,CAF,140,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,50.2,Total,Units,%,Estimated value,Free,,Total
Central African Republic,CF,CAF,140,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,39.0,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,18.0,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,21.6,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,29.4,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,48.4,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,68.4,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,53.1,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,50.4,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,55.0,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,64.9,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,72.3,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,72.0,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,73.1,Total,Units,%,Estimated value,Free,,Total
Chad,TD,TCD,148,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,64.8,Total,Units,%,Estimated value,Free,,Total
Colombia,CO,COL,170,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,42.2,Total,Units,%,Estimated value,Free,,Total
Colombia,CO,COL,170,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,49.8,Total,Units,%,Estimated value,Free,,Total
Colombia,CO,COL,170,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,51.0,Total,Units,%,Estimated value,Free,,Total
Colombia,CO,COL,170,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,53.9,Total,Units,%,Estimated value,Free,,Total
Colombia,CO,COL,170,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,60.7,Total,Units,%,Estimated value,Free,,Total
Colombia,CO,COL,170,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,51.9,Total,Units,%,Estimated value,Free,,Total
Colombia,CO,COL,170,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,55.4,Total,Units,%,Estimated value,Free,,Total
Colombia,CO,COL,170,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,57.2,Total,Units,%,Estimated value,Free,,Total
Colombia,CO,COL,170,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,55.7,Total,Units,%,Estimated value,Free,,Total
Colombia,CO,COL,170,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,56.3,Total,Units,%,Estimated value,Free,,Total
Colombia,CO,COL,170,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,55.0,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,10.9,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,24.1,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,18.9,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,24.3,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,19.5,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,18.4,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,10.7,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,10.8,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,7.2,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,7.3,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,12.0,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,21.0,Total,Units,%,Estimated value,Free,,Total
Congo,CG,COG,178,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,19.5,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,<1,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,<1,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,<1,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,42.7,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,52.8,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,92.1,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,94.4,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,>95,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,92.4,Total,Units,%,Estimated value,Free,,Total
Costa Rica,CR,CRI,188,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,54.9,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,87.6,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,>95,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,72.5,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,63.0,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,>95,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,88.3,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,91.0,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Cuba,CU,CUB,192,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,46.2,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,44.4,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,58.4,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,74.1,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,86.4,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,89.3,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,87.8,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,91.7,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,91.8,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,86.2,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,81.7,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,84.5,Total,Units,%,Estimated value,Free,,Total
Ivory Coast,CI,CIV,384,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,79.5,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,3.2,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,<1,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,2.9,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,9.5,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,38.4,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,53.9,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,48.6,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,39.7,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,51.8,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,45.2,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,40.7,Total,Units,%,Estimated value,Free,,Total
"Congo, the Democratic Republic of the",CD,COD,180,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,37.2,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,32.7,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,47.0,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,58.6,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,44.7,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,50.7,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,43.3,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,45.3,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,40.8,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,38.7,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,33.2,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,26.6,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,44.4,Total,Units,%,Estimated value,Free,,Total
Dominican Republic,DO,DOM,214,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,58.3,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,39.4,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,41.8,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,45.2,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,46.0,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,47.4,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,48.7,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,50.1,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,50.6,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,51.5,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,79.4,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,61.4,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,76.3,Total,Units,%,Estimated value,Free,,Total
Ecuador,EC,ECU,218,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,89.7,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,4.4,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,2.5,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,2.8,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,10.7,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,8.2,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,7.6,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,12.4,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,12.1,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,12.5,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,14.3,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,16.0,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,26.9,Total,Units,%,Estimated value,Free,,Total
Egypt,EG,EGY,818,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,27.5,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,38.6,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,45.1,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,64.5,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,73.8,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,70.4,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,69.3,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,65.2,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,67.5,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,58.1,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,67.2,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,59.3,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,75.6,Total,Units,%,Estimated value,Free,,Total
El Salvador,SV,SLV,222,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,77.8,Total,Units,%,Estimated value,Free,,Total
Equatorial Guinea,GQ,GNQ,226,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,13.0,Total,Units,%,Estimated value,Free,,Total
Equatorial Guinea,GQ,GNQ,226,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,6.9,Total,Units,%,Estimated value,Free,,Total
Equatorial Guinea,GQ,GNQ,226,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,11.3,Total,Units,%,Estimated value,Free,,Total
Equatorial Guinea,GQ,GNQ,226,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,49.3,Total,Units,%,Estimated value,Free,,Total
Equatorial Guinea,GQ,GNQ,226,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,48.1,Total,Units,%,Estimated value,Free,,Total
Equatorial Guinea,GQ,GNQ,226,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,38.0,Total,Units,%,Estimated value,Free,,Total
Equatorial Guinea,GQ,GNQ,226,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,59.0,Total,Units,%,Estimated value,Free,,Total
Equatorial Guinea,GQ,GNQ,226,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,54.3,Total,Units,%,Estimated value,Free,,Total
Equatorial Guinea,GQ,GNQ,226,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,44.5,Total,Units,%,Estimated value,Free,,Total
Equatorial Guinea,GQ,GNQ,226,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,44.3,Total,Units,%,Estimated value,Free,,Total
Equatorial Guinea,GQ,GNQ,226,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,32.2,Total,Units,%,Estimated value,Free,,Total
Equatorial Guinea,GQ,GNQ,226,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,42.4,Total,Units,%,Estimated value,Free,,Total
Equatorial Guinea,GQ,GNQ,226,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,47.3,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,37.2,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,59.5,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,>95,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,>95,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,>95,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,>95,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,80.4,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,90.8,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,89.4,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,84.3,Total,Units,%,Estimated value,Free,,Total
Eritrea,ER,ERI,232,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,93.3,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,68.7,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,85.4,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,83.3,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,83.8,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,76.9,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,83.9,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,87.3,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,80.4,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,94.1,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,89.0,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Swaziland,SZ,SWZ,748,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,24.3,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,37.0,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,58.6,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,69.1,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,70.6,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,77.4,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,69.8,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,66.9,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,77.8,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,82.9,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,92.5,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,80.1,Total,Units,%,Estimated value,Free,,Total
Ethiopia,ET,ETH,231,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,85.9,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,36.0,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,63.0,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,64.5,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,32.4,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,44.7,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,33.3,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,54.3,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,78.0,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,69.6,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,35.5,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,48.5,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,40.8,Total,Units,%,Estimated value,Free,,Total
Fiji,FJ,FJI,242,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,35.7,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,19.9,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,26.3,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,33.9,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,44.3,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,45.8,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,56.2,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,72.0,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,68.5,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,75.6,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,81.4,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,77.1,Total,Units,%,Estimated value,Free,,Total
Gabon,GA,GAB,266,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,81.7,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,41.6,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,55.8,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,47.1,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,48.8,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,48.8,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,59.9,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,52.5,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,52.0,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,50.7,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,47.1,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,45.4,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,60.6,Total,Units,%,Estimated value,Free,,Total
Gambia,GM,GMB,270,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,59.0,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,34.2,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,46.8,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,51.4,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,41.7,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,48.4,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,45.3,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,57.4,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,65.2,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,68.9,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,70.9,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,76.5,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,93.3,Total,Units,%,Estimated value,Free,,Total
Ghana,GH,GHA,288,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,84.8,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,23.7,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,31.4,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,23.1,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,36.5,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,32.5,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,20.2,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,25.6,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,27.3,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,33.6,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,33.9,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,34.6,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,38.7,Total,Units,%,Estimated value,Free,,Total
Guatemala,GT,GTM,320,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,44.3,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,19.0,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,33.7,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,34.0,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,67.3,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,<1,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,<1,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,<1,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,<1,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,<1,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,52.7,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,58.0,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,61.1,Total,Units,%,Estimated value,Free,,Total
Guinea,GN,GIN,324,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,56.0,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,16.8,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,24.3,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,37.2,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,61.0,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,>95,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,88.5,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,86.6,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,86.7,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,64.7,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,78.7,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,80.4,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,59.6,Total,Units,%,Estimated value,Free,,Total
Guinea-Bissau,GW,GNB,624,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,60.3,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,39.5,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,49.7,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,53.5,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,69.8,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,56.6,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,62.3,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,59.0,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,48.1,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,56.8,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,64.3,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,50.0,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,70.1,Total,Units,%,Estimated value,Free,,Total
Guyana,GY,GUY,328,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,87.1,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,47.1,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,77.3,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,>95,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,>95,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,91.1,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,87.4,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,80.6,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,86.0,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,91.2,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,87.8,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,71.6,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,68.2,Total,Units,%,Estimated value,Free,,Total
Haiti,HT,HTI,332,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,62.3,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,33.2,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,34.5,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,39.0,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,37.1,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,38.6,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,36.1,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,38.2,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,42.0,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,49.9,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,40.8,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,36.0,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,40.5,Total,Units,%,Estimated value,Free,,Total
Honduras,HN,HND,340,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,41.4,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,2.7,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,1.6,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,3.1,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,4.5,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,6.4,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,8.4,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,10.6,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,13.5,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,16.3,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,18.0,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,17.4,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,15.2,Total,Units,%,Estimated value,Free,,Total
Indonesia,ID,IDN,360,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,18.0,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,13.7,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,17.0,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,26.9,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,28.3,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,35.0,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,27.0,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,35.7,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,38.4,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,45.0,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,44.4,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,44.7,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,41.2,Total,Units,%,Estimated value,Free,,Total
"Iran, Islamic Republic of",IR,IRN,364,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,37.4,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,56.0,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,45.8,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,45.8,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,46.1,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,64.7,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,74.2,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,74.3,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,76.5,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,76.1,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,79.2,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,63.8,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,76.0,Total,Units,%,Estimated value,Free,,Total
Jamaica,JM,JAM,388,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,76.7,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,52.8,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,72.3,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,58.9,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,61.0,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,71.5,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,90.9,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,92.8,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,85.2,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Kenya,KE,KEN,404,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,89.6,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,48.1,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,35.5,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,63.2,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,68.3,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,73.5,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,53.4,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,67.5,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,70.2,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,73.5,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,71.0,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,93.9,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,91.5,Total,Units,%,Estimated value,Free,,Total
Kyrgyzstan,KG,KGZ,417,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,12.4,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,22.9,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,22.6,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,25.0,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,14.0,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,15.6,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,35.0,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,35.1,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,41.3,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,30.6,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,36.4,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,60.7,Total,Units,%,Estimated value,Free,,Total
Lao People's Democratic Republic,LA,LAO,418,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,54.3,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,66.4,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,91.4,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,92.6,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,89.9,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,>95,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,>95,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,93.9,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,77.1,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,87.5,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,85.9,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,90.0,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,86.8,Total,Units,%,Estimated value,Free,,Total
Lesotho,LS,LSO,426,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,89.4,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,21.2,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,31.6,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,32.9,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,26.4,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,28.2,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,54.4,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,66.5,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,76.9,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,91.4,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,93.5,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,69.6,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Liberia,LR,LBR,430,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,86.3,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,<1,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,<1,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,<1,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,<1,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,<1,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,<1,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,57.6,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,56.4,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,68.1,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,67.4,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,65.6,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,66.0,Total,Units,%,Estimated value,Free,,Total
Libyan Arab Jamahiriya,LY,LBY,434,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,67.4,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,1.7,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,9.2,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,5.9,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,4.2,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,3.5,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,2.9,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,1.5,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,4.7,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,11.4,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,12.8,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,9.1,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,12.5,Total,Units,%,Estimated value,Free,,Total
Madagascar,MG,MDG,450,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,12.4,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,26.3,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,48.1,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,58.2,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,66.0,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,70.0,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,79.6,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,85.4,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,92.2,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,94.9,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Malawi,MW,MWI,454,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,90.5,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,63.7,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,66.7,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,65.8,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,63.0,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,70.1,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,79.4,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,>95,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,>95,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Malaysia,MY,MYS,458,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,36.1,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,50.1,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,54.2,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,32.4,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,35.6,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,41.0,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,37.2,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,36.8,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,38.4,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,31.1,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,32.1,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,38.6,Total,Units,%,Estimated value,Free,,Total
Mali,ML,MLI,466,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,33.1,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,8.3,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,8.8,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,4.2,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,9.0,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,57.8,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,53.8,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,17.3,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,12.1,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,19.4,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,34.5,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,20.0,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,7.3,Total,Units,%,Estimated value,Free,,Total
Mauritania,MR,MRT,478,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,22.5,Total,Units,%,Estimated value,Free,,Total
Morocco,MA,MAR,504,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,21.5,Total,Units,%,Estimated value,Free,,Total
Morocco,MA,MAR,504,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,21.3,Total,Units,%,Estimated value,Free,,Total
Morocco,MA,MAR,504,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,33.7,Total,Units,%,Estimated value,Free,,Total
Morocco,MA,MAR,504,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,31.7,Total,Units,%,Estimated value,Free,,Total
Morocco,MA,MAR,504,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,37.0,Total,Units,%,Estimated value,Free,,Total
Morocco,MA,MAR,504,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,31.4,Total,Units,%,Estimated value,Free,,Total
Morocco,MA,MAR,504,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,41.1,Total,Units,%,Estimated value,Free,,Total
Morocco,MA,MAR,504,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,40.9,Total,Units,%,Estimated value,Free,,Total
Morocco,MA,MAR,504,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,44.5,Total,Units,%,Estimated value,Free,,Total
Morocco,MA,MAR,504,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,55.1,Total,Units,%,Estimated value,Free,,Total
Morocco,MA,MAR,504,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,52.1,Total,Units,%,Estimated value,Free,,Total
Morocco,MA,MAR,504,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,52.4,Total,Units,%,Estimated value,Free,,Total
Morocco,MA,MAR,504,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,62.8,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,20.8,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,44.3,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,68.7,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,73.3,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,82.6,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,84.1,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,78.1,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,86.4,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,86.9,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,88.7,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,84.3,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,88.8,Total,Units,%,Estimated value,Free,,Total
Mozambique,MZ,MOZ,508,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,92.5,Total,Units,%,Estimated value,Free,,Total
Burma,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,41.4,Total,Units,%,Estimated value,Free,,Total
Burma,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,49.6,Total,Units,%,Estimated value,Free,,Total
Burma,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,57.3,Total,Units,%,Estimated value,Free,,Total
Burma,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,60.6,Total,Units,%,Estimated value,Free,,Total
Burma,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,70.6,Total,Units,%,Estimated value,Free,,Total
Burma,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,74.0,Total,Units,%,Estimated value,Free,,Total
Burma,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,81.0,Total,Units,%,Estimated value,Free,,Total
Burma,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,81.7,Total,Units,%,Estimated value,Free,,Total
Burma,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,86.1,Total,Units,%,Estimated value,Free,,Total
Burma,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,86.0,Total,Units,%,Estimated value,Free,,Total
Burma,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,81.4,Total,Units,%,Estimated value,Free,,Total
Burma,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,21.9,Total,Units,%,Estimated value,Free,,Total
Burma,MM,MMR,104,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,43.3,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,65.7,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,71.2,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,63.1,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,79.8,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,92.5,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,>95,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,>95,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,>95,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Namibia,,NAM,516,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,15.1,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,23.0,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,29.4,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,35.2,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,43.1,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,41.2,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,55.0,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,62.2,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,50.9,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,45.7,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,48.2,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,73.5,Total,Units,%,Estimated value,Free,,Total
Nepal,NP,NPL,524,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,80.2,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,67.6,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,89.2,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,>95,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,79.0,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,78.5,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,90.9,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,83.1,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,79.9,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,83.1,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,91.3,Total,Units,%,Estimated value,Free,,Total
Nicaragua,NI,NIC,558,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,79.1,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,60.4,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,52.6,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,52.1,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,62.5,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,41.3,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,66.2,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,42.0,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,39.9,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,33.5,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,27.4,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,26.4,Total,Units,%,Estimated value,Free,,Total
Niger,NE,NER,562,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,32.0,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,3.1,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,7.4,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,3.9,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,9.7,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,4.0,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,12.2,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,6.7,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,8.9,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,14.4,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,17.3,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,4.9,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,18.3,Total,Units,%,Estimated value,Free,,Total
Pakistan,PK,PAK,586,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,12.2,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,68.4,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,77.6,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,76.4,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,88.4,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,75.1,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,82.0,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,75.4,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,80.1,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,73.8,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,64.6,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,62.9,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,83.8,Total,Units,%,Estimated value,Free,,Total
Panama,PA,PAN,591,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,73.9,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,4.5,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,13.6,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,20.9,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,27.8,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,34.5,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,29.0,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,33.1,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,40.3,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,50.3,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,64.2,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,47.1,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,51.6,Total,Units,%,Estimated value,Free,,Total
Papua New Guinea,PG,PNG,598,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,50.7,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,56.7,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,64.3,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,64.5,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,63.2,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,74.9,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,61.4,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,63.7,Total,Units,%,Estimated value,Free,,Total
Paraguay,PY,PRY,600,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,59.3,Total,Units,%,Estimated value,Free,,Total
Peru,PE,PER,604,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,36.5,Total,Units,%,Estimated value,Free,,Total
Peru,PE,PER,604,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,55.4,Total,Units,%,Estimated value,Free,,Total
Peru,PE,PER,604,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,66.2,Total,Units,%,Estimated value,Free,,Total
Peru,PE,PER,604,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,68.3,Total,Units,%,Estimated value,Free,,Total
Peru,PE,PER,604,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,69.2,Total,Units,%,Estimated value,Free,,Total
Peru,PE,PER,604,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,64.4,Total,Units,%,Estimated value,Free,,Total
Peru,PE,PER,604,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,67.2,Total,Units,%,Estimated value,Free,,Total
Peru,PE,PER,604,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,68.6,Total,Units,%,Estimated value,Free,,Total
Peru,PE,PER,604,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,78.5,Total,Units,%,Estimated value,Free,,Total
Peru,PE,PER,604,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,85.8,Total,Units,%,Estimated value,Free,,Total
Peru,PE,PER,604,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,85.5,Total,Units,%,Estimated value,Free,,Total
Peru,PE,PER,604,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,80.4,Total,Units,%,Estimated value,Free,,Total
Peru,PE,PER,604,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,84.3,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,13.6,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,16.4,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,13.9,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,8.5,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,11.9,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,13.9,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,15.8,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,16.4,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,17.5,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,21.8,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,21.5,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,13.3,Total,Units,%,Estimated value,Free,,Total
Philippines,PH,PHL,608,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,6.4,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,67.6,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,65.1,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,67.5,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,64.0,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,72.0,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,77.1,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,79.4,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,88.6,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,79.6,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,88.8,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,77.6,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,86.6,Total,Units,%,Estimated value,Free,,Total
"Moldova, Republic of",MD,MDA,498,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,69.6,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,91.1,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,91.5,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Rwanda,RW,RWA,646,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Sao Tome and Principe,ST,STP,678,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,31.3,Total,Units,%,Estimated value,Free,,Total
Sao Tome and Principe,ST,STP,678,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,33.0,Total,Units,%,Estimated value,Free,,Total
Sao Tome and Principe,ST,STP,678,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,43.8,Total,Units,%,Estimated value,Free,,Total
Sao Tome and Principe,ST,STP,678,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,30.1,Total,Units,%,Estimated value,Free,,Total
Sao Tome and Principe,ST,STP,678,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,50.0,Total,Units,%,Estimated value,Free,,Total
Sao Tome and Principe,ST,STP,678,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,54.8,Total,Units,%,Estimated value,Free,,Total
Sao Tome and Principe,ST,STP,678,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,44.1,Total,Units,%,Estimated value,Free,,Total
Sao Tome and Principe,ST,STP,678,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,46.9,Total,Units,%,Estimated value,Free,,Total
Sao Tome and Principe,ST,STP,678,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,48.4,Total,Units,%,Estimated value,Free,,Total
Sao Tome and Principe,ST,STP,678,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,76.3,Total,Units,%,Estimated value,Free,,Total
Sao Tome and Principe,ST,STP,678,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,80.4,Total,Units,%,Estimated value,Free,,Total
Sao Tome and Principe,ST,STP,678,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,83.3,Total,Units,%,Estimated value,Free,,Total
Sao Tome and Principe,ST,STP,678,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,86.5,Total,Units,%,Estimated value,Free,,Total
Saudi Arabia,SA,SAU,682,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,<1,Total,Units,%,Estimated value,Free,,Total
Saudi Arabia,SA,SAU,682,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,29.3,Total,Units,%,Estimated value,Free,,Total
Saudi Arabia,SA,SAU,682,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,36.8,Total,Units,%,Estimated value,Free,,Total
Saudi Arabia,SA,SAU,682,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,53.2,Total,Units,%,Estimated value,Free,,Total
Saudi Arabia,SA,SAU,682,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,51.5,Total,Units,%,Estimated value,Free,,Total
Saudi Arabia,SA,SAU,682,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,79.0,Total,Units,%,Estimated value,Free,,Total
Saudi Arabia,SA,SAU,682,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,>95,Total,Units,%,Estimated value,Free,,Total
Saudi Arabia,SA,SAU,682,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,89.1,Total,Units,%,Estimated value,Free,,Total
Saudi Arabia,SA,SAU,682,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,79.6,Total,Units,%,Estimated value,Free,,Total
Saudi Arabia,SA,SAU,682,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,70.4,Total,Units,%,Estimated value,Free,,Total
Saudi Arabia,SA,SAU,682,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,73.7,Total,Units,%,Estimated value,Free,,Total
Saudi Arabia,SA,SAU,682,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,73.7,Total,Units,%,Estimated value,Free,,Total
Saudi Arabia,SA,SAU,682,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,48.4,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,21.5,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,26.3,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,31.5,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,46.8,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,41.2,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,53.2,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,56.4,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,53.3,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,62.3,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,66.3,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,66.0,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,66.0,Total,Units,%,Estimated value,Free,,Total
Senegal,SN,SEN,686,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,72.4,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,34.8,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,45.5,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,59.5,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,51.8,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,48.7,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,59.2,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,59.9,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,66.5,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,73.3,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,67.3,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,61.6,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,93.1,Total,Units,%,Estimated value,Free,,Total
Sierra Leone,SL,SLE,694,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,68.7,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,85.0,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,88.8,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
South Africa,ZA,ZAF,710,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,7.3,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,9.7,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,10.8,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,19.5,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,18.3,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,42.4,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,29.3,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,62.3,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,70.9,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,58.1,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,59.5,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,56.6,Total,Units,%,Estimated value,Free,,Total
South Sudan,SS,SSD,728,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,53.1,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,4.8,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,4.2,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,5.1,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,4.1,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,6.0,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,6.1,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,4.8,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,6.9,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,5.0,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,3.3,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,2.8,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,2.4,Total,Units,%,Estimated value,Free,,Total
Sudan,SD,SDN,736,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,5.8,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,63.0,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,91.5,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,88.8,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,87.0,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,90.8,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,>95,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,86.4,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,76.1,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,72.5,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,68.8,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,71.9,Total,Units,%,Estimated value,Free,,Total
Suriname,SR,SUR,740,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,62.4,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,94.2,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,94.5,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,94.3,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,94.0,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,94.9,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,>95,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,>95,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,>95,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Thailand,TH,THA,764,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,30.9,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,64.7,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,71.1,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,74.6,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,77.4,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,82.8,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,88.6,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,72.6,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,82.6,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,84.2,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,73.5,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,75.2,Total,Units,%,Estimated value,Free,,Total
Togo,TG,TGO,768,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,79.3,Total,Units,%,Estimated value,Free,,Total
Trinidad and Tobago,TT,TTO,780,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,66.4,Total,Units,%,Estimated value,Free,,Total
Trinidad and Tobago,TT,TTO,780,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,85.2,Total,Units,%,Estimated value,Free,,Total
Trinidad and Tobago,TT,TTO,780,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,91.8,Total,Units,%,Estimated value,Free,,Total
Trinidad and Tobago,TT,TTO,780,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,70.9,Total,Units,%,Estimated value,Free,,Total
Trinidad and Tobago,TT,TTO,780,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,64.4,Total,Units,%,Estimated value,Free,,Total
Trinidad and Tobago,TT,TTO,780,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,58.5,Total,Units,%,Estimated value,Free,,Total
Trinidad and Tobago,TT,TTO,780,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,83.8,Total,Units,%,Estimated value,Free,,Total
Trinidad and Tobago,TT,TTO,780,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,84.3,Total,Units,%,Estimated value,Free,,Total
Trinidad and Tobago,TT,TTO,780,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,91.0,Total,Units,%,Estimated value,Free,,Total
Trinidad and Tobago,TT,TTO,780,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,90.6,Total,Units,%,Estimated value,Free,,Total
Trinidad and Tobago,TT,TTO,780,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Trinidad and Tobago,TT,TTO,780,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Trinidad and Tobago,TT,TTO,780,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,91.7,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,8.8,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,10.1,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,9.5,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,12.0,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,25.7,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,16.5,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,11.9,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,11.0,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,12.0,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,17.6,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,27.8,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,30.8,Total,Units,%,Estimated value,Free,,Total
Tunisia,TN,TUN,788,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,40.2,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,35.2,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,58.6,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,93.4,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,>95,Total,Units,%,Estimated value,Free,,Total
Uganda,UG,UGA,800,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,>95,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,60.2,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,77.5,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,>95,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,>95,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,93.6,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,87.7,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,83.3,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,91.8,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,93.7,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,91.2,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,89.0,Total,Units,%,Estimated value,Free,,Total
"Tanzania, United Republic of",TZ,TZA,834,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,91.6,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,12.7,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,22.8,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,83.6,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,80.3,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,74.5,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,76.8,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,73.3,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,53.8,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,60.0,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,60.6,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,57.7,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,65.3,Total,Units,%,Estimated value,Free,,Total
Uzbekistan,UZ,UZB,860,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,67.2,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,9.1,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,10.1,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,13.2,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,16.2,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,20.8,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,20.7,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,20.9,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,17.3,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,19.1,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,13.7,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,17.3,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,21.7,Total,Units,%,Estimated value,Free,,Total
"Venezuela, Bolivarian Republic of",VE,VEN,862,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,37.3,Total,Units,%,Estimated value,Free,,Total
Viet Nam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,52.1,Total,Units,%,Estimated value,Free,,Total
Viet Nam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,44.5,Total,Units,%,Estimated value,Free,,Total
Viet Nam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,46.0,Total,Units,%,Estimated value,Free,,Total
Viet Nam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,42.0,Total,Units,%,Estimated value,Free,,Total
Viet Nam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,58.5,Total,Units,%,Estimated value,Free,,Total
Viet Nam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,62.5,Total,Units,%,Estimated value,Free,,Total
Viet Nam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,72.0,Total,Units,%,Estimated value,Free,,Total
Viet Nam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,79.6,Total,Units,%,Estimated value,Free,,Total
Viet Nam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,83.3,Total,Units,%,Estimated value,Free,,Total
Viet Nam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,94.1,Total,Units,%,Estimated value,Free,,Total
Viet Nam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,>95,Total,Units,%,Estimated value,Free,,Total
Viet Nam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,83.7,Total,Units,%,Estimated value,Free,,Total
Viet Nam,VN,VNM,704,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,76.8,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,8.6,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,2.9,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,5.4,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,6.8,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,5.0,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,2.4,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,<1,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,3.2,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,3.1,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,6.9,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,3.4,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,7.1,Total,Units,%,Estimated value,Free,,Total
Yemen,YE,YEM,887,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,23.8,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,62.4,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,65.5,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,70.0,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,79.2,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,85.4,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,79.8,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,84.3,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,90.4,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,86.0,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,90.5,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,92.1,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,91.0,Total,Units,%,Estimated value,Free,,Total
Zambia,ZM,ZMB,894,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,90.6,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2010,29.8,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2011,48.3,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2012,75.3,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2013,74.6,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2014,81.1,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2015,81.1,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2016,86.7,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2017,90.5,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2018,92.5,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2019,93.7,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2020,87.9,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2021,85.4,Total,Units,%,Estimated value,Free,,Total
Zimbabwe,ZW,ZWE,716,Per cent of pregnant women living with HIV receiving effective ARVs for PMTCT (excludes single-dose nevirapine),2022,84.6,Total,Units,%,Estimated value,Free,,Total
